Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome

Rheumatology International

Volumn 33, Issue 9, 2013, Pages 2331-2336

  Singh, N K ^a   Gupta, A ^a   Behera, Dibya R ^a   Dash, D ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Antiphospholipid syndrome; Plasminogen activator inhibitor type 1 (PAI 1); Thrombosis

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMAN; MALE; MORBIDITY; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIPHOSPHOLIPID SYNDROME; FEMALE; FIBRINOLYSIS; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; THROMBOPHILIA;

EID: 84883149217     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2717-0     Document Type: Article

References (30)

1. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309-1311
2. Hughes GR (1983) Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J 287:1088-1089
3. Alarcon-Segovia D, Deleze M, Oria CV et al (1989) Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore) 68:353-365
4. Arnold J, Holmes Z, Pickering W, Farmer C, Regan L, Cohen H (2001) Anti-beta 2 glycoprotein 1 and anti-annexin V antibodies in women with recurrent miscarriage. Br J Haematol 113:911-914
5. Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J et al (1997) Pregnancy loss in the antiphospholipid antibody syndrome - a possible thrombogenic mechanism. New Engl J Med 17:154-160
6. Ruiz-Arguelles G, Ruiz-Arguelles A, Alarcon-Segovia D, Drenkar C, Villa A, Cabiedes J et al (1991) Natural anticoagulants in systemic lupus erythematosus: deficiency of protein S bound to C4 bp associates with recent history of venous thromboses, antiphospholipid antibodies, and the antiphospholipid syndrome. J Rheumatol 18:552-558
7. Cosgriff PM, Martin BA (1981) Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis. Arthritis Rheum 24:94-96
8. Rand JH, Wu XX, Andree HA, Ross JB, Rusinova E, Gascon-Lema MG et al (1998) Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a lupus "procoagulant" phenomenon. Blood 92:165260
9. Arnout J, Vermylen J (1998) Mechanisms of action of β-2-glycoprotein I-dependent lupus anticoagulants. Lupus 7(suppl. 2):23-28
10. Kornberg A, Renadineau Y, Blank M, Youinou P, Shoenfeld Y (2000) Anti-beta 2-glycoprotein I antibodies and anti-endothelial cell antibodies induce tissue factor in endothelial cells. Isr Med Assoc J 2(Suppl 2):27-31
11. Carreras LO, de Freyn G, Machin SJ, Vermylen JG, Deman R, Spitz B et al (1981) Arterial thrombosis, intrauterine death and 'lupus' anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1:244-246
12. Forastiero R, Martinuzzo M, Carreras LO, Maclouf J (1998) Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb Haemost 79:42-45
13. Urbanus RT, Derksen RH, de Groot PG (2008) Platelets and the antiphospholipid syndrome. Lupus 17:888
14. Zorio E, Gilabert-Estelles J, Espana F et al (2008) Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 15:923-929
15. Castellino FJ, Ploplis VA (2005) Structure and function of plasminogen/plasmin system. Thromb Haemost 93:647-654
16. Huber K (2001) Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role of thromboembolic diseases. J Thromb Thrombolysis 11:183-193
17. Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295-306
18. Ames PR, Tommasino C, Iannaccone L et al (1996) Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - a crucial role for acquired free protein S deficiency. Thromb Haemost 76:190-194
19. Juardo M, Paramo JA, Gutierrez-Pimentel M, Rocha E (1992) Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost 68:516-520
20. Coulam CB, Wallis D, Weinstein J, DasGupta DS, Jeyendran RS (2008) Comparison of thrombophilia gene mutations among patients experiencing recurrent miscarriages and deep vein thrombosis. Am J Reprod Immunol 60(5):426-431
21. Landin K, Tengborn L, Smith V (1990) Elevated fibrinogen and plasminogen activator (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 227:273-278
22. Juhan-Vague I, Alessi MC, Vague P (1991) Increased plasma plasminogen activator inhibitor levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 34:457-462
23. Sobel BE, Woodcock-Mitchell J, Schneider DJ (1998) Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients. Circulation 97:2213-2221
24. Hendrinks HFJ, Veenstgra J, Velthuis-teWierik EJM et al (1994) Effect of moderate dose of alcohol with evening meal on brinolytic factors. Br Med J 308:1003-1005
25. Pralong G, Calandra T, Glauser MP et al (1989) Plasminogen activator inhibitor-1: a new prognostic marker in septic shock. Thromb Haemost 61:459-462
26. Sartori MT, Winman B, Veltore S et al (1998) 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep venous thrombosis. Thromb Haemost 80:956-960
27. Glueck CJ, Fontaine RN, Gupta A et al (1997) Myocardial infarction in a 35-year-old man with homocysteinemia, high plasminogen activator inhibitor activity and resistance to activated protein C. Metabolism 46:1470-1472
28. Margaglione M, Cappusi G, d'Addedda M et al (1998) PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environment and genetic determinants. Arterioscler Thromb Vasc Biol 18:562-567
29. Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G (2008) The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 122:736-742
30. Yasuda S, Tsutsumi A, Atsumi T, Bertolaccini ML, Ichikawa K, Khamashta MA, Hughes GR, Koike T (2002) Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies. J Rheumatol 29(6):1192-1197